Cargando…

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China

Detalles Bibliográficos
Autores principales:	Liu, Jia, Cao, Lidan, Wu, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683105/ https://www.ncbi.nlm.nih.gov/pubmed/36438279 http://dx.doi.org/10.3389/fpubh.2022.1059495

Ejemplares similares

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
por: Liu, Jia, et al.
Publicado: (2022)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
por: Meng, Rui, et al.
Publicado: (2022)

The clinical utility of lurasidone in schizophrenia: patient considerations
por: Harvey, Philip D
Publicado: (2015)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
por: Shao, Taihang, et al.
Publicado: (2022)

Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
por: Li, Wei, et al.
Publicado: (2022)

Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom
por: Dymond, Amy, et al.
Publicado: (2022)

Lurasidone for the treatment of schizophrenia in adult and paediatric populations
por: Guilera, Teresa, et al.
Publicado: (2023)

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis
por: Yan, Jianzhou, et al.
Publicado: (2022)

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
por: Lou, Yake, et al.
Publicado: (2022)

Clinical potential of lurasidone in the management of schizophrenia
por: Samalin, Ludovic, et al.
Publicado: (2011)

Critical appraisal of lurasidone in the management of schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2012)

Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia
por: Javed, Afzal, et al.
Publicado: (2019)

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia
por: Meltzer, Herbert Y., et al.
Publicado: (2020)

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
por: Miura, Itaru, et al.
Publicado: (2023)

Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
por: Ye, Zhuo-miao, et al.
Publicado: (2023)

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Update on the development of lurasidone as a treatment for patients with acute schizophrenia
por: Yasui-Furukori, Norio
Publicado: (2012)

Identification of clinical phenotypes in schizophrenia: the role of lurasidone
por: Riva, Marco Andrea, et al.
Publicado: (2021)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
por: Liu, Qiao, et al.
Publicado: (2020)

Psychological and sleep disturbances among first-line, second-line, and at home medical staff during the COVID-19 pandemic in Shanghai, China
por: Wang, Ping, et al.
Publicado: (2022)

Corrigendum: Landscape and predictions of inflammatory bowel disease in China: China will enter the Compounding Prevalence stage around 2030
por: Shao, Bule, et al.
Publicado: (2022)

Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
por: Ogasa, Masaaki, et al.
Publicado: (2012)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice
por: Fagiolini, Andrea, et al.
Publicado: (2022)

Lurasidone augmentation to clozapine in treatment resistant schizophrenia: A pilot study
por: Arienti, V., et al.
Publicado: (2023)

Schizophrenia relapse, patient considerations, and potential role of lurasidone
por: Citrome, Leslie
Publicado: (2016)

Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2023)

Corrigendum: The cost of firearm violent crime in British Columbia, Canada
por: Rajabali, Fahra, et al.
Publicado: (2023)

Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR
por: Restelli, Umberto, et al.
Publicado: (2020)

Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
por: Hu, Jia, et al.
Publicado: (2022)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China
por: Xiang, Guiyuan, et al.
Publicado: (2021)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
por: Zhou, Hui Jun, et al.
Publicado: (2021)

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
por: Zhao, Mingye, et al.
Publicado: (2023)

Cost-Utility Analysis of the Integrated Care Models for the Management of Hypertension Patients: A Quasi-Experiment in Southwest Rural China
por: Ke, Xiatong, et al.
Publicado: (2021)

The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis
por: Thomas, Jennifer E., et al.
Publicado: (2015)

Real-world treatment patterns and outcomes in patients initiating lurasidone for the treatment of schizophrenia in Europe
por: Jones, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t6nd76r0i048js0365904kjnum